Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.59 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22605478 | 1.00 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL342295 | 1.00 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL2604450 | 1.00 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| Hydrochloric Acid SCHEMBL15273446 | 0.98 | CHRM1 (0.60) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| Hydrochloric Acid SCHEMBL16444395 | 0.98 | CHRM1 (0.60) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL319049 | 0.92 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL8863517 | 0.92 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL8863418 | 0.92 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL8863420 | 0.92 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL22605488 | 0.86 | CHRM1 (0.56) | CHRM1CHRM2CHRM4CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | disclosed |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | disclosed |
| US-7495109-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495109-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156640-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | CHRM1 242/4885CHRM2 369/4885CHRM4 231/4885 |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | CHRM1 242/4885CHRM2 369/4885CHRM4 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.